Indeed, the IL-6 receptor-inhibiting monoclonal antibody tocilizumab has resulted in increased weight gain and hyperlipidemia in humans (5), and there are analogous signaling and metabolic phenotypes associated with ablation of IL-1 and IL-6. This evidence concerns the gene IL6 and hyperlipidemia.